Non Small Cell Lung Cancer (NSCLC)

Stage IV/Metastatic - 2nd Line - Immunotherapy

- No Prior Therapy With PD-1/PD-L1
  - THOR0006
    - Phase I/II of Nivolumab with Ipilimumab in Refractory Thoracic Tumors
      - PI: Wakelee NCIN
  - LUN0088
    - Phase II
      - Radical-Dose RT with Anti-PD-1 Anti-PD-L1 Immunotherapy in Non-Small Cell Lung Cancer
        - PI: Gensheimer Stanford
      - THOR0006
        - Phase I/II of Nivolumab with Ipilimumab in Refractory Thoracic Tumors
          - PI: Wakelee NCTN
        - LUN0117
          - Phase III
            - Atezolizumab +/- Cabozantinib vs Docetaxel Monotherapy in Metastatic Non-Small Cell Lung Cancer
              - PI: Neal Sponsor: Hoffman La Roche
            - LUN0107
              - Phase Ib/II
                - Grapiprant +/- Pembrolizumab in Advanced or Metastatic Post-PD-1/PD-L1 NSCLC Adenocarcinoma
                  - PI: Wakelee Arvs Therapeutics
              - ECOG ACRIEA5191
                - Phase II
                  - Cabozantinib +/- Nivolumab vs Standard Chemotherapy in Previously Treated Non-Squamous NSCLC
                    - PI: Neal Pending

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold